Amarin Announces Research Evaluating Benefits Of VASCEPA/VAZKEPA To Be Presented At The American College Of Cardiology's Annual Scientific Session & Expo
Amarin Announces Research Evaluating Benefits Of VASCEPA/VAZKEPA To Be Presented At The American College Of Cardiology's Annual Scientific Session & Expo
Amarin宣布评估VASCEPA/VAZKEPA益处的研究将在美国心脏病学会的年度科学会议和博览会上发表
-- Subgroup Analyses from REDUCE-IT and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting --
--来自 REDUCE-IT 的子组分析 以及会议上介绍的二十碳五烯乙基（IPE）/二十碳五烯酸（EPA）的机械数据——
DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional patient subgroup analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology's Annual Scientific Session & Expo, April 6 – 8, 2024 in Atlanta, GA.
爱尔兰都柏林和新泽西州布里奇沃特，2024年3月25日（GLOBE NEWSWIRE）——Amarin Corporation plc（纳斯达克股票代码：AMRN）今天宣布，来自具有里程碑意义的REDUCE-IT结果试验的更多患者亚组分析以及有关二十碳五烯酸（IPE）/二十碳五烯酸（EPA）的机制数据将在4月的美国心脏病学会年度科学会议和博览会上公布 2024 年 6 — 8 日在乔治亚州亚特兰大举行。
"The data being featured at ACC.24 continues to support and explain the clinical utility and value of VASCEPA/VAZKEPA (icosapent ethyl), not only in...
医学博士纳比尔·阿巴迪尔说：“ACC.24上公布...
登录免费看全文
登录/注册